Related coverage linked through entity extraction aliases.
Mar 19, 2026
Research into Lynch syndrome is advancing cancer prevention through aspirin therapy, vaccine trials, and a major North American study examining why some patients develop cancer while others remain protected.
Feb 26, 2026
Daily aspirin use does not prevent bowel cancer in the general population within 5-15 years and carries immediate bleeding risks, according to a new Cochrane review. However, long-term low-dose aspirin is associated with lower colorectal cancer risk in IBD patients.
Feb 26, 2026
Lynch syndrome patients gain access to prevention vaccines in clinical trials, while immunotherapy advances depend on universal tumor testing for microsatellite instability. Cancer vaccines are moving from research to clinical reality.
Feb 17, 2026
New research identifies circulating tumor-reactive T cell characteristics and inflammatory biomarkers as predictive indicators for immune checkpoint inhibitor response in cancer patients, while the PD-L1 testing market is projected to reach $36.44 billion by 2032.
